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Abstract
Gastric cancer is one of the most common causes of cancer-related mortality worldwide. Expression of the tumor
suppressor, promyelocytic leukemia (PML) protein, is reduced or abolished in gastric carcinomas, in association with an
increased level of lymphatic invasion, development of higher pTNM staging, and unfavorable prognosis. Herein, we
investigated the relationship between the extent of tumor-infiltrating lymphocytes and the status of PML protein
expression in advanced gastric carcinoma. We observed higher numbers of infiltrating T-cells in gastric carcinoma tissues in
which PML expression was reduced or abolished, compared to tissues positive for PML. The extent of T-cell migration
toward culture supernatants obtained from interferon-gamma (IFN-c-stimulated gastric carcinoma cell lines was additionally
affected by expression of PML in vitro. Interferon-gamma-inducible protein 10 (IP-10/CXCL10) expression was increased in
gastric carcinoma tissues displaying reduced PML levels. Moreover, both Pml knockout and knockdown cells displayed
enhanced IP-10 mRNA and protein expression in the presence of IFN-c. PML knockdown increased IFN-c-mediated Signal
Transducer and Activator of Transcription-1 (STAT-1) binding to the IP-10 promoter, resulting in elevated transcription of the
IP-10 gene. Conversely, PML IV protein expression suppressed IP-10 promoter activation. Based on these results, we propose
that loss of PML protein expression in gastric cancer cells contributes to increased IP-10 transcription via enhancement of
STAT-1 activity, which, in turn, promotes lymphocyte trafficking within tumor regions.
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Introduction
Gastric cancer is one of the most frequent causes of cancer-related
deaths worldwide. Recent advances in genetics have facilitated the
detection of events occurring during the course of gastric
carcinogenesis, including activation of oncogenes, silencing of tumor
suppressor genes, and mutation of genes involved inDNA repair [1].
Among these genetic events, it is known that tumor suppressor
promyelocytic leukemia (PML) protein expression is reduced or
abolished in gastric cancer, and that this is associated with more
extensive lymphatic invasion, higher pTNM staging, and unfavor-
able prognosis, suggesting that PML loss is linked to carcinogenesis
and gastric carcinoma progression [2]. Earlier studies implicated Pml
dysfunction in progression of a variety of cancers, and reduced or
abolished expression of PML has been reported in prostate, breast,
CNS, colon, lung, and gastric cancers [2,3].
The Pml gene was originally identified by fusion with the
retinoic acid receptor involved in the t(15;17) chromosomal
translocation associated with acute promyelocytic leukemia
(APL) [4,5,6,7,8]. PML is a tumor suppressor protein that
regulates cell cycle progression, gene transcription, transformation
suppression, and apoptosis. Pml knockout mice are considerably
more sensitive to tumor formation after exposure to carcinogens
than are wild-type controls, and Pml-deficient cells are less likely to
undergo apoptosis after application of particular types of cellular
stress [9]. In addition to reports focusing on the tumor suppressor
role played by PML, several studies have confirmed that the
protein acts as a transcriptional regulator, via association with the
co-activator CREB-binding protein; co-repressors including
HDAC, N-CoR, and mSin3A; and the transcription factors
Nur77, AP-1, myc, p53, and STAT-1a [10,11,12,13,14,15,16,17].
Progressive mutation of and genetic alterations in several tumor
suppressor genes promote tumor development and progression
[18]. In addition to genetic alterations within tumor cells, both
inflammatory cells and mediators contribute to formation of
particular tumor microenvironments [19,20]. Tumor-associated
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26264fibroblasts (TAFs) and macrophages (TAMs) are also involved in
modulation of the tumor microenvironment via production of
cytokines, chemokines, interferons, and other biologically active
factors [21,22]. Cross-talk among tumor cells, TAFs, TAMs, and
lymphocytes, is significant in tumor development and progression,
and contributes to establishment of tumor microenvironments
enriched in expression of a variety of biologically active factors
[23,24,25,26,27].
TAMs are found to correlate with angiogenesis and an
unfavorable prognosis in several types of cancer, including gastric
cancer [22,28]. Mast cell produces many angiogenic factors and a
variety of cytokines, and its density has been reported to highly
correlate with the extent of tumor neoangiogenesis and poor
prognosis [29,30]. CD4
+ and CD8
+ lymphocytes are also found in
a variety of solid cancer tissues. Until now, the precise molecular
mechanisms by which the type and the number of tumor
infiltrating cells are regulated are largely unknown. There are
several controversial reports with regard to the number and
function of tumor-infiltrating lymphocytes. Especially, CD8
+ T
lymphocytes, while their function is known to eliminate nascent
transformed cells and contribute to immunosurveillance [31], it is
reported that CD8
+ tumor-infiltrating T cells are defective in
effector phase function upon contact with tumor cells [32], and
their infiltration is linked to unfavorable prognosis in certain types
of cancer such as nonsmall cell lung cancer and nasopharyngeal
carcinoma [33,34].
Chemokines secreted by stromal cells or tumor cells influence
tumor cell migration, invasion, proliferation, angiogenesis and
immune cell infiltration in the tumor mass [35]. IFN-c-inducible
protein-10 (IP-10, CXCL10) is one of the CXC chemokines which
plays multiple roles in inflammatory diseases and cancer [36,37].
Since IP-10 preferentially promotes Th1 immune responses by
robustly attracting NK and T cells, it is suggested as one of
possible mechanisms of T cell infiltration to tumors.
Whether loss of tumor suppressor genes in tumor cells induces
recruitment of lymphocytes and modulation of the functions of
such cells within tumor microenvironments is currently unclear. In
the present study, we examined PML function with respect to
recruitment of lymphocytes and modulation of the expression of
tumor-derived factors. Expression of PML was inversely correlated
with the extent of infiltration of CD8
+ T-cells into gastric
carcinomas. PML loss was further associated with enhanced
expression of IP-10, one of the lymphocyte-attracting CXC
chemokines, in gastric carcinoma cells and tissues. PML
knockdown promoted IFN-c-mediated STAT-1 binding to the
IP-10 promoter, resulting in increased transcription of the IP-10
gene. Our data support the notion that PML is involved in
recruitment of lymphocytes into tumors, via modulation of the
expression levels of tumor-derived factors including IP-10,
providing further evidence that the loss of tumor suppressor genes
in tumor cells actively participates in the establishment of tumor
microenvironments.
Results
Loss of PML protein is associated with increased
infiltration of CD8
+ T-cells into advanced gastric
carcinoma tissue
Immunohistochemical staining for PML and CD8 was per-
formed to explore whether the extent of lymphocyte infiltration
was associated with PML expression status in advanced gastric
cancer. CD8-immunopositive cells were enumerated as described
in Materials and Methods. In total, 35 samples (71.4%) showed
partial-to-complete loss of PML in the tumor cell nuclei of stage IV
advanced gastric carcinomas. Samples from 14 advanced gastric
carcinoma patients were diffusely positive for PML, and contained
an average of 32.7 CD8
+ T-cells per field (Figure 1A). We
identified 19 instances of advanced gastric carcinoma exhibiting
focal positivity for PML, with an average of 47.2 CD8
+ T-cells per
field. Moreover, complete loss of PML was observed in 16
advanced gastric carcinoma patients; the samples contained an
average number of 52.8 CD8
+ T-cells per field. Samples displaying
focal positivity or complete loss for PML showed a more marked
increase in CD8
+ T-cell number than did specimens exhibiting
diffuse positivity for PML. Representative images are shown in
Figure 1B. Although PML protein expression was reduced or
abolished in tumor cells, all of normal gastric mucosal glands,
stromal tissues, and lymphoid cells, exhibited diffuse moderate-to-
strong nuclear immunopositivity for PML.
PML influences T-cell infiltration/migration in vitro
In view of the loss of PML protein expression and the increase
in infiltration of CD8
+ T-lymphocytes into advanced gastric
carcinoma tissues, we hypothesized that PML contributed to T-
cell infiltration/migration in gastric cancer. To explore whether
the PML level in gastric cancer cells influenced T-cell migration,
conditioned media from SNU-638 cells transiently transfected
with either Pml siRNA or PML IV expression vector, then treated
with IFN-c was utilized in transwell migration assays. SNU-638
gastric cancer cells expressed high levels of PML protein,
consistent with previous findings [2], whereas SNU-638 cells
transfected with Pml siRNA displayed reduced levels of endoge-
nous PML expression (,46–56%), as confirmed by immunoblot-
ting (Figure 2A). IFN-c induced a modest increase in PML protein
expression, in agreement with previous results [38]. Migration of
Jurkat T-cells toward conditioned medium from Pml siRNA-
transfected SNU-638 cells was significantly enhanced, compared
to that of control siRNA-transfected cells, after treatment with
IFN-c (Figure 2B). Upon transfection of SNU-638 with PML IV
expression vector, migration of Jurkat T-cells toward conditioned
medium from PML IV overexpressed cells was reduced compared
to that of empty vector (Figure 2C). These results suggest that
PML regulates the levels of secretory molecules produced by and
released from IFN-c-stimulated gastric cancer cells, and also
influences the migration of T- lymphocytes.
Loss of PML enhances IFN-c-induced IP-10 expression
Chemokines, a family of chemotactic cytokines, promote migra-
tion of circulating leukocytes/lymphocytes to sites of inflammation
and injury. To explore whether chemokine levels were affected by
Pml genetic status, chemokine gene expression was examined using
ribonuclease protection assay (RPA). Pml
+/+ and Pml
2/2 mouse
embryonic fibroblast (MEF) cells were incubated in the absence or
presence of IFN-c for 0-24 h, total mRNA was collected at various
timepoints, and subjected to RPA. In Pml
2/2 MEFs, IP-10 mRNA
levels increased 1.5-fold at 2 h, and became markedly elevated (8-
fold) by 4 h (Figure 3A). RANTES mRNA levels were increased
3.2-fold at 0.5 h, and remained elevated, but to a lower extent
(1.3-fold), 8 h post-IFN-c treatment in Pml
2/2 MEFs. Other
chemokine genes, including MIP-1, MIP-2, and MCP-1, were not
detectably expressed in Pml
+/+ or Pml
2/2 MEFs (data not shown).
STAT-1 expression was increased after exposure to IFN-c in both
cell types, but no difference was evident when IFN-c levels were
compared between Pml
+/+ and Pml
2/2 cells. As transcription of
the IP-10 gene was substantially elevated in IFN-c-stimulated
Pml
2/2 MEFs, we measured relevant protein levels in culture
supernatants of Pml
+/+ and Pml
2/2 MEFs, using an enzyme-linked
immunosorbent assay (ELISA). Consistent with the RPA results,
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from IFN-c-treated Pml
2/2 MEFs (Figure 3B). Also, IP-10 mRNA
expression in Pml siRNA-transfected NIH3T3 cells was enhanced,
compared to that of control siRNA-transfected cells, following
IFN-c treatment (Figure 3C). The reduction in expression of PML
protein in Pml siRNA-transfected NIH3T3 cells was confirmed by
immunoblotting.
Reduced PML expression is inversely correlated with IP-
10 protein levels in gastric cancer tissue and SNU-638
cells
Next, we examined the relationship between IP-10 and PML
protein expression in advanced gastric carcinoma tissue. Cancer
tissues were immunohistochemically stained for PML and IP-10,
and the intensity of IP-10 immunopositivity was measured as
described in Materials and Methods. The average intensity of IP-
10 was 1.2 in 14 samples showing diffuse positivity (DP) for PML,
2.2 in 19 instances of focal positivity (FP), and 2.0 in 16 samples in
which there was complete loss (CL) of PML expression (Figure 4A,
left panel). Significant increases in IP-10 expression were observed
in samples showing focal positivity of PML (P=0.034), compared
to those showing diffuse positive PML expression. An increase in
IP-10 expression was observed when complete loss of PML was
evident, compared with what was noted when PML was diffusely
expressed; however, this difference did not reach statistical
significance. Representative examples of variations in PML
protein status that correlated with different IP-10 expression levels
in tumor cells from advanced gastric carcinomas are shown
(Figure 4A, right). To further examine the relationship between
IP-10 and PML protein expression in gastric carcinoma cell lines,
IP-10 protein levels were measured in culture supernatants from
SNU-638 cells transiently transfected with either Pml siRNA or
PML IV exression vector. Cells were grown in the absence or
presence of IFN-c for 8 h, supernatants collected, and IP-10 levels
quantified therein (by ELISA). IFN-c-induced IP-10 secretion was
significantly enhanced in SNU-638-Pml siRNA-transfected cells,
compared with that of SNU-638 cells transfected with control
siRNA (Figure 4B). Transfection of SNU-638 with PML IV
expression vector suppressed IFN-c-induced IP-10 secretion
(Fig 4C). The results clearly show that secretion of IP-10 from
gastric cancer cells is increased when PML expression is reduced.
IP-10 neutralization decreases migration of T-cells
As SNU-638-Pml siRNA-containing cells expressing reduced
levels of PML protein showed enhancement of T-cell recruitment
and IP-10 secretion in response to IFN-c (Figures 2 and 4), we next
examined whether an increase in IP-10 levels facilitated T-cell
migration toward conditioned medium from SNU-638 gastric
cancer cells stimulated by IFN-c. SNU-638-Pml siRNA cells were
grown in the absence or presence of IFN-c for 8 h, and the
collected supernatants were pretreated with an anti-IP-10
neutralizing antibody or control non-specific IgG for 1 h, prior
to commencement of the transwell assay. Neutralizing antibody or
IgG-containing supernatants were placed in the lower chambers,
and migration of Jurkat cells from upper to lower chambers was
analyzed by examining cells harvested from the lower chambers.
Figure 1. Promyelocytic Leukemia (PML) Protein Expression is Inversely Correlated with the Extent of Infiltration of CD8
+ T-cells in
Advanced Gastric Carcinoma Tissues. (A) Immunohistochemical staining for PML protein and CD8 was performed for 49 cases of stage IV
advanced gastric carcinomas. Immunopositivity for PML protein was categorized as diffuse positivity (DP; nuclear immunoreactivity in $50% of
tumor cells, n=14), focal positivity (FP; in $10% but ,50%, n=19), or complete loss (CL; in ,10%, n=16). The number of CD8 immunopositive cells
in one high power field (HPF, x40) of 0.25 mm
2 for five randomly selected tumor infiltrative borders were counted for each specimen, followed by
calculation of the mean and SD. (B) Representative images showing PML protein expression and CD8
+ T-cell infiltration in advanced gastric carcinoma
tissues. Bars, SD. *P,0.05.
doi:10.1371/journal.pone.0026264.g001
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migration toward conditioned medium from SNU-638-Pml siRNA
cells (Figure 5A). These findings are consistent with data obtained
from NIH3T3 cells; an IP-10-neutralizing antibody inhibited EL-4
T-cell migration toward conditioned medium from NIH3T3-Pml
siRNA cells (Figure 5B).
PML knockdown enhances IP-10 promoter activation
As IP-10 expression was increased in PML knockdown cells, we
further explored whether PML protein expression affected IP-10
promoter activity. The murine IP-10 promoter contains a putative
GAS-like element lying between nts -246 and -238 (TTN5AA)
(Figure 6A). We previously reported that PML negatively regulates
Figure 2. Reduced PML Protein Expression by siRNA Increases T-cell Infiltration/Migration. (A) SNU-638 gastric cancer cells were
transiently transfected with Pml siRNA or control siRNA. Two days after transfection, cells were treated with or without interferon-gamma (IFN-c
(10 ng/ml) for 8 h and lysed and analyzed by immunoblotting. Effective siRNA-mediated suppression of PML protein expression was verified for each
assay by immunoblotting. (B) Jurkat cells and culture supernatants from SNU-638 cells which were transiently transfected with either control siRNA or
Pml siRNA were analyzed by a transwell migration assay. After transfection, SNU-638 cells were incubated with IFN-c (10 ng/ml) for 8 h or left
untreated, and the collected supernatants were placed in the lower chambers. The upper chambers received 5610
5 Jurkat cells in a volume of 100 ml
and the transwell migration units were incubated at 37uC for 2 h. Migration of Jurkat cells from the upper to lower chamber was analyzed by
examining cells harvested from the lower chambers by fluorescent count-bead mediated counting on a flow cytometer. Relative cell migration was
determined by the number of migrated cells normalized to the number of cells migrating to supernatants from SNU-638 cells transiently transfected
with control siRNA without IFN-c, and the value from parental cells was arbitrarily set at 1. (C) SNU-638 gastric cancer cells were transiently
transfected with either empty vector (Mock) or PML IV expression vector (PML IV). Day after transfection, cells were treated with or without IFN-c
(10 ng/ml) for 8 h and culture supernatants were obtained and subjected to transwell migration assay as described in B. PML protein expression was
verified for each assay by immunoblotting. Data shown are representative of at least three experiments. Bars, SD. *P,0.05.
doi:10.1371/journal.pone.0026264.g002
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PML affected IFN-c-induced IP-10 gene expression via a
mechanism involving STAT-1, we isolated and generated a
reporter construct commencing at position -330 of the murine IP-
10 promoter containing the putative GAS-like element, as
described in Materials and Methods. The IP-10-luc reporter
containing the GAS-like element was transiently transfected into
NIH3T3 cells incubated with or without IFN-c for 24 h, and
subsequently assayed for luciferase activity. IFN-c-induced IP-10
promoter activity was significantly enhanced in NIH3T3 cells
transfected with Pml siRNA, compared to cells receiving control
siRNA (Figure 6B). Upon transfection of NIH3T3 cells with the
PML IV expression vector, IFN-c-induced IP-10 promoter
activation was significantly repressed. Downregulation of PML
expression using Pml siRNA and overexpression of PML by PML
IV expression vector were verified by immunoblotting. To
determine whether the inhibitory effect of PML on IFN-c-induced
IP-10 promoter activity is occurred in gastric cancer cells lines, we
Figure 3. Expression Levels of IFN-c-inducible protein-10 (IP-10) are Enhanced in Pml
2/2 MEFs compared to Pml
+/+ wild-type cells.
(A) RNA from Pml
+/+ and Pml
2/2 MEFs treated with IFN-c (10 ng/ml) for 0-24 h was subjected to ribonuclease protection assay (RPA). Quantification
of IP-10, RANTES and STAT-1 mRNA (FOLD INCREASE) was calculated by dividing the densitometric value of each lane by the corresponding GAPDH
value. (B) Pml
+/+ and Pml
2/2 MEFs cells were incubated in the absence or presence of IFN-c (10 ng/ml) for 12 h. IP-10 protein from the culture
supernatants were analyzed by ELISA and normalized by the cell protein concentration. The relative concentration was calculated as the normalized
amount divided by the normalized amount of untreated Pml
2/2 MEFs cells. (C) NIH3T3 fibroblasts were transiently transfected with either Pml siRNA
or control siRNA. Two days after transfection, cells were treated with or without IFN-c for 0-24 h, and analyzed by immunoblotting for detection of
PML protein expression and RT-PCR for IP-10 mRNA. Quantification (Quant) of IP-10 mRNA was calculated by dividing the densitometric value of each
lane by the corresponding actin mRNA value. Data shown are representative of at least three experiments. Bars, SD. *P,0.01.
doi:10.1371/journal.pone.0026264.g003
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The patterns of increase and decrease in the luciferase activity in
SNU-638 were similar to that of NIH3T3 cells (Figure 6C). The
level of PML protein expression in SNU-638 cells transfected with
either Pml siRNA or PML IV expression vector was verified by
immunoblotting (data not shown).
Figure 4. PML Protein Expression is Inversely Correlated with the Level of IP-10. (A) Immunohistochemical staining for PML and IP-10
protein expression was performed for 49 cases of stage IV advanced gastric carcinomas. Immunopositivity for PML protein was categorized as
diffuse positivity (DP; nuclear immunoreactivity in $50% of tumor cells), focal positivity (FP; in $10% but ,50%), or complete loss (CL; in
,10%). For quantitative analysis of immunoreactivity of IP-10, positively stained areas were measured using an ImageJ software program as
described in Materials and Methods. Representative images show PML and IP-10 protein expression in advanced gastric carcinoma tissues
(right). (B) SNU-638 cells were transiently transfected with Pml siRNA or control siRNA. Two days after transfection, cells were incubated in the
absence or presence of IFN-c (10 ng/ml) for 8 h. IP-10 protein from the culture supernatants was analyzed by ELISA and normalized by the cell
protein concentration. The relative concentration was calculated as the normalized amount divided by the normalized amount of SNU-638 cells
which were transiently transfected with control siRNA in the presence of IFN-c, and the concentration from parental cells was arbitrarily set at
100%. (C) SNU-638 gastric cancer cells were transiently transfected with either empty vector or PML IV expression vector. Day after transfection,
cells were treated with or without IFN-c (10 ng/ml) for 8 h and culture supernatants were obtained and subjected to ELISA as described in B.
PML protein expression was verified for each assay by immunoblotting. Data shown are representative of at least three experiments. Bars, SD.
*P,0.05, **P,0.01.
doi:10.1371/journal.pone.0026264.g004
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binding to the IP-10 promoter
The effect of PML on IFN-c-induced STAT-1 DNA binding to
the IP-10 promoter was further examined. PML protein
overexpression in NIH3T3 cells, after transient transfection with
the PML IV expression vector, partially blocked IFN-c-induced
STAT-1 DNA binding to the IP-10 promoter, including the
sequence at -246 to -238 (Figure 7A, compare lanes 3 and 5).
Competition using a 100-molar excess unlabeled oligonucleotide
encoding the IP-10 promoter abrogated complex formation (lane
6). The levels of PML and STAT-1 protein expression in whole-
cell lysates (WCL) and the extent of STAT-1 tyrosine phosphor-
ylation in nuclear extracts (NE) were verified by immunoblotting.
Utilizing NE from NIH3T3-Pml siRNA cells obtained after 0.5 h
of IFN-c treatment, strong binding to the murine IP-10 promoter
was observed (Figure 7B, top panel, lane 5), compared to binding
seen in NIH3T3-control siRNA cells (lane 3). The same NEs were
exposed to the STAT-1 consensus oligonucleotide, and STAT-1
DNA binding was enhanced in NE from NIH3T3-Pml siRNA cells
(Figure 7B, middle panel, compare lanes 3 and 5). Using SNU-638
gastric cancer cells, we also found that STAT-1 DNA binding of
Pml siRNA-transfected SNU-638 cells was enhanced compared to
that of control siRNA-transfected cells, after treatment with IFN-c
(Figure 7C, compare lanes 3 and 5). These data indicate that PML
partially inhibits STAT-1 binding to the IP-10 promoter, and that
this effect is correlated with increased IFN-c-induced IP-10
transcription in the absence of PML.
Discussion
Histopathologic studies have shown that the inflammatory
microenvironment of tumors is characterized by the presence of
mononuclear cell infiltrates, both in the supporting stroma and
tumor regions. However, the precise mechanisms by which
mononuclear cells infiltrate into and are sustained within cancer
tissues are currently not fully understood. In the present study, we
offer evidence that loss of expression of the tumor suppressor
protein, PML, contributes to enhancement of lymphocyte infiltra-
tion into gastric cancer tissue, via regulation of IP-10 expression.
We examined the function of PML with respect to lymphocyte
recruitment using human gastric cancer tissue samples, Pml
+/+ and
Pml
2/2 MEFs, and PML knockdown in both NIH3T3 and SNU-
638 cells. Data obtained from both human tissue tests and the
transwell migration assays showed that loss of PML promotes
lymphocyte trafficking; thus, we sought mechanisms that might
possibly explain these observations. We show that an increase in
IP-10 levels in cancer cells expressing low levels of PML con-
tributes to lymphocyte recruitment. Additionally, IP-10 neutraliz-
ing antibody inhibited T-cell migration toward conditioned
medium from NIH3T3 fibroblasts and SNU-638 gastric cancer
cells in vitro, consistent with the results of several prior in vivo
studies, which showed that neutralization of IP-10 suppressed T-
cell recruitment [39,40]. To the best of our knowledge, this is the
first study showing that the tumor suppressor, PML, regulates IP-
10 chemokine transcription and lymphocyte trafficking in gastric
cancer, by modulating the activity of the IFN-c/STAT-1 signaling
pathway.
IP-10, a lymphocyte-targeting CXC chemokine induced by type
I and II IFNs, plays an important role in lymphocyte recruitment
under several inflammatory conditions [41]. IP-10 is secreted by
tumor-infiltrating immune cells, and also by tumoral and paren-
chyma cells in an interferon- and cytokine-enriched microenvi-
ronment. TAFs from lung cancer patients constitutively produce
and secrete IP-10 [27]. Hepatocytes infected with the hepatitis C
virus produce IP-10, and induce migration of activated T-cells to
the liver parenchyma, indicating that IP-10 levels are correlated
with histological severity and inflammation [42]. In our system,
IP-10 secretion was observed in gastric cancer SNU-638 cells,
NIH3T3 fibroblasts, and MEFs, in response to IFN-c, and
secretion was enhanced in the absence of PML protein expression.
Since we found that there were no appreciable differences in the
level of STAT-1 expression and phosphorylation in the absence or
presence of PML upon IFN-c (Figures 3 and 7), increased IFN-c-
induced IP-10 transcription in the absence of PML was caused
mainly by enhanced STAT-1 DNA binding to IP-10 promoter.
We suggest that PML-mediated inhibition of STAT-1 DNA
binding leads to suppression of STAT-1-dependent IP-10 expres-
sion, in accord with our previous findings [17]. In the present
study, we identify a potential regulatory region for PML in the IP-
10 promoter, which is a putative STAT-1-binding site. Further, we
Figure 5. IP-10 Neutralization Inhibits the Migration of T Cells.
(A) SNU-638-Pml siRNA cells were grown in the absence or presence of
IFN-c (10 ng/ml) for 8 h, and supernatant was collected and pretreated
with IP-10 neutralizing antibodies (5 mg/ml) or IgG (5 mg/ml) for 1 h
prior to initiation of the transwell migration assay. The number of
migrating Jurkat cells obtained from the lower chamber was analyzed
by fluorescent count-bead mediated counting on a flow cytometer. (B)
Transwell migration of EL-4 cells to culture supernatants from NIH3T3
cells transiently transfected with Pml siRNA in the presence of
neutralizing IP-10 antibody or IgG control. Relative cell migration was
determined by the number of the migrated cells divided by the number
of cells migrating to supernatants without IFN-c, and the value from
parental cells was arbitrarily set at 1. Data shown are representative of
at least three experiments. Bars, SD. *P,0.05.
doi:10.1371/journal.pone.0026264.g005
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DNA binding to the IP-10 promoter, and enhances IP-10 levels in
the absence of PML.
Lymphocytes, neutrophils, macrophages, and mast cells are the
major components of most tumor infiltrates. Tumor-infiltrating
lymphocytes have been identified in a variety of solid cancer
tissues. However, the specific functions of such cells within tumors,
and the precise molecular mechanisms of lymphocyte recruitment
into tumors, remain controversial. The status and functional
relevance of CD8
+ T-cell infiltration into tumors, and the
association of such cells with patient prognosis, are also unclear.
In renal cell carcinoma, infiltration of CD8
+ T-cells is associated
with favorable prognosis [43]. Conversely, such infiltration is
linked to unfavorable prognosis in nonsmall cell lung cancer
patients [33]. We here show that PML protein expression in tumor
cells is inversely correlated with the extent of infiltration of CD8
+
Figure 6. PML Expression Represses IFN-c-inducible IP-10 Promoter Activity. (A) The murine IP-10 promoter contains a putative GAS-like
element (underlined). (B) NIH3T3 cells were co-transfected with the IP-10-luc reporter containing a GAS-like element and/or Pml siRNA, or the PML IV
protein expression vector. Cells were either untreated or treated with murine IFN-c (10 ng/ml) for 24 h, and then luciferase activity was determined.
The pCMV-b-galactosidase vector was included to normalize transfection efficiency. Luciferase activity is normalized to the activity in the absence of
IFN-c and the activity from parental cells was arbitrarily set at 100% (RLA; relative luciferase activity). Increased or reduced PML protein expression in
cell lysates transfected with either PML IV expression vector or Pml siRNA was verified by immunoblotting, respectively. (C) SNU-638 gastric cancer
cells were co-transfected with the IP-10-luc reporter containing a GAS-like element and/or Pml siRNA, or the PML IV protein expression vector and
analyzed as described in B. Values are the mean 6 SD of three separate experiments. Bars, SD. *P,0.05, **P,0.001.
doi:10.1371/journal.pone.0026264.g006
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PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26264Figure 7. PML Expression Inhibits DNA Binding Activity of STAT-1 to the IP-10 Promoter. (A) Nuclear extracts (NE) from NIH3T3 cells
transiently transfected with the PML IV protein expression vector and treated with IFN-c (10 ng/ml) for 30 min were incubated in the presence of a
radiolabeled DNA probe containing the GAS-like element of the IP-10 promoter, and subjected to electrophoretic mobility shift assay (EMSA). Shifted
probe-protein complexes are indicated by the arrow. Increased PML protein expression in whole-cell lysates (WCL) transfected with PML IV expression
vector was verified by immunoblotting. The amount of histone in NE is shown as a control. (B) NEs from NIH3T3 cells transiently transfected with
either Pml siRNA or control siRNA and treated with IFN-c (10 ng/ml) for 30 min were incubated in the presence of radiolabeled DNA probes
containing the GAS-like element of the IP-10 promoter or a STAT-1 consensus sequence, and then subjected to EMSA. Binding specificity was tested
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invasion is considered together with the association between PML
expression and unfavorable prognosis [2], it is apparent that any
relationship between clinical features and the extent of CD8
+ T-cell
infiltration in gastric cancer patients requires further elucidation.
Nuclei of normal gastric mucosal glands, stromal tissues, and
lymphoid cells were diffusely immunopositive (moderate-to-strong)
for PML protein expression, whereas PML levels were reduced or
abolished in tumor cells (Figure 1). These findings support the idea
that cancer cells have specific degradation mechanisms for PML.
We would propose that post-translational proteasome-dependent
degradation explains the loss of PML protein. In other words,
degradation at the transcriptional level is not operative [2,44].
PML protein expression is reduced or abolished in many different
cancers, including prostate, breast, CNS, colon, lung, and gastric
cancer [2,3]. Consistent with these results, we observed reduced or
negligible expression of PML in advanced gastric cancer tissues.
Moreover, our results suggest that cancer cells expressing different
levels of PML protein vary in their capacity to attract and retain
lymphocytes in tumor areas, thus providing further evidence that
such cells actively participate in the establishment of inflammatory
tumor microenvironments, via PML-mediated mechanisms.
NF-kB and STAT-3 signaling are proposed to serve as major
regulatory systems linking inflammation to cancer [45]. IL-6, an NF-
kB-dependent inflammatory growth factor, is essential for develop-
ment of inflammation-associated carcinogenesis [46]. Recent
circumstantial evidence has further strengthened the idea that the
IL-6/gp130/STAT-3 signaling axis serves as both an autocrine and
paracrine amplification loop in lung adenocarcinoma, multiple
myeloma, Ras-transformed cancer cells, and a colitis-associated
cancer model [47,48,49,50]. PML has been shown to suppress IL-6-
induced STAT-3 activity [51], to promote apoptosis via aT N F -
mediated process, and to sensitize cells to apoptosis by inhibiting the
NF-kB-mediated survival pathway [52]. However, it remains to be
established whether loss of the tumor suppressor PML contributes to
changes in the host immune response or the tumor microenviron-
ment, perhaps resulting in either immunosurveillance or immune
escape, by modulation of transcription factors. Thus, it would be
interesting to compare the effects of loss of PML protein expression
on NF-kB/STAT-3 and STAT-1 signaling, and to determine
whetherthesetranscriptionfactorsfunctionina coordinated manner
to regulate the expression of a subset of chemokines contributing to
the establishment of inflammatory tumor microenvironments.
Materials and Methods
Cells
Primary and immortalized Pml
+/+ and Pml
2/2 MEFs were
established and maintained as previously described [53]. The
SNU-638 human gastric carconoma cell line, Jurkat human T-cell
lymphoblast-like cell line, and EL-4 mouse T-lymphoma cell lines
were maintained as previously described [2,54].
Gastric carcinoma tissues
A total of 49 gastric carcinoma paraffin blocks were obtained
from 49 patients (29 males; 20 females; median age 64 years; range
35–84) who had undergone total or subtotal gastrectomy for stage
IV advanced gastric carcinomas at Mokdong Hospital, Ewha
Womans University School of Medicine, Seoul, Korea from 2001
to 2007.
Reagents and antibodies
Recombinant murine and human IFN-c (mIFN-c and hIFN-c)
and mIP-10 and hIP-10 were purchased from ProSpec (Rehovot,
Israel). Antibodies to PML (mouse monoclonal) and STAT-1 were
purchased from Upstate Biotechnology, Inc. (Lake Placid, NY,
USA) and neutralizing antibody to IP-10 was purchased from
R&D Systems (Minneapolis, MN, USA). Antibody to p-Y701-
STAT-1 was purchased from Cell Signaling Technology (Beverly,
MA). Antibodies to histone, Lamin B and PML (rabbit polyclonal)
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), and anti-tubulin antibody was purchased from Sigma-
Aldrich, Co. (St. Louis, MO, USA).
Immunohistochemistry, cell counts, and measurement of
immunoreactive areas
Human gastric cancer tissues were processed for immunohis-
tochemical analysis as described previously [2] with minor
modifications. Primary antibodies for PML (1:200; Santa Cruz
Biotechnology), CD8 (1:50; Thermo Fisher Scientific, Fremont,
CA, USA), and IP-10 (1:50; R&D Systems) were utilized. All slides
were counterstained with Mayer’s hematoxylin. Positive controls
were obtained using palatine tonsils for PML protein and CD8,
and nasopharyngeal undifferentiated carcinomas for IP-10.
Negative controls were obtained by omitting primary antibodies
from all slides. Immunopositivity for PML protein was categorized
as diffuse positivity (nuclear immunoreactivity in $50% of tumor
cells), focal positivity (in $10% but ,50%), or complete loss (in
,10% of tumor cells). The numbers of CD8 immunopositive cells
in one high power field (HPF, x40) of 0.25 mm
2 for five randomly
selected tumor infiltrative borders were counted for each
specimen, followed by calculation of the mean number and SD.
Immunopositivity for IP-10 was defined as any nuclear or
cytoplasmic positive expression in tumor cells. For determining
the expressed level of each slide, digital images were obtained
using a microscope-mounted digital camera. Using ImageJ
software (http://rsb.info.nih.gov/ij), each image was converted
to 8-bit gray scale and area densities were measured from the
pixels in the region of interest; only pixels exceeding a certain level
(.50 intensity value) were included to eliminate background error.
siRNA transfection
NIH3T3 cells were transiently transfected using Mirus trans-
fection reagent (Mirus Bio LLC, Madison, WI, USA) or
Lipofectamine
TM RNAiMAX (Invitrogen, Carlsbad, CA, USA)
with either 300 nmol of mPML siRNA or negative control siRNA
(Samchully Pharm, Co. Ltd., Seoul, Korea), according to the
manufacturer’s instructions. The human gastric carcinoma cell
line SNU-638 was also transfected using Mirus reagent or
Lipofectamine
TM RNAiMAX with either 100 nmol of hPML
siRNA (Santa Cruz Biotechnology) or negative control siRNA.
Cells were allowed to recover for 48 h before treatment with
10 ng/ml of IFN-c for various times, and then analyzed by
immunoblotting and/or RT-PCR.
by adding increasing concentrations of cold probe (competitor). Effective siRNA-mediated suppression of PML protein expression was verified for
each assay by immunoblotting. (C) SNU-638 gastric cancer cells were transiently transfected with either Pml siRNA or control siRNA and treated with
IFN-c (10 ng/ml) for 30 min. NEs were obtained, incubated in the presence of radiolabeled DNA probes containing a STAT-1 consensus sequence, and
then analyzed for EMSA as described in B. The levels of PML and STAT-1 protein expression in WCL and the extent of STAT-1 tyrosine phosphorylation
in NE were verified by immunoblotting. Data shown are representative of at least three experiments.
doi:10.1371/journal.pone.0026264.g007
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Cells were plated, incubated with IFN-c (10 ng/ml) for 0–24 h,
and then lysed with lysis buffer [17]. Twenty mg sample of total
protein or5 mg ofnuclearprotein was subjected toSDS/PAGE, and
blots were probed with PML, histone or tubulin antibodies. After
secondary antibody incubation, blots were developed using ECL
chemiluminescence system (Amersham, Buckinghamshire, UK).
Transwell migration assay
In vitro migration assays were performed using Costar Transwell
Inserts with a 5-mm pore size in 24-well plates (Corning Costar,
Cambridge, MA, USA). SNU-638 cells were stimulated with IFN-c
(10 ng/ml) for 0–8 h, and 600 ml of the supernatants were placed in
the lower chambers of transwell migration units. The upper
chambers received 5610
5 Jurkat or EL-4 cells in a volume of 100 ml
and the transwell migration units were incubated at 37uC for 2 h.
The numbers of migrating cells obtained from the lower chambers
were analyzed by fluorescent count-bead mediated counting on a
flow cytometer (BD Biosciences, San Jose, CA, USA). For
neutralization, the supernatants were pretreated with an anti-IP-
10 neutralizing antibody or control non-specific IgG for 1 h, then
placed in the lower chambers, and migrating cells harvested from
the lower chamber were similarly determined.





seeded and treated with IFN-c (10 ng/ml) for 12 h, then the
concentration of IP-10 in supernatants was determined using a
mouse IP-10 ELISA Kit (R&D Systems), according to the
manufacturer’s instructions. SNU-638 cells (2.4610
5 cells/well)
were transiently transfected with either negative control siRNA or
PML siRNA for 48 h, then treated with IFN-c for 8 h. IP-10
protein levels in cell culture supernatants were measured using a
human IP-10 BD optEIA
TM (BD Biosciences) and normalized by
the cell protein concentration.
RNA isolation, RT-PCR, and RPA
Total cellular RNA was isolated from confluent monolayers of
cells using easy-BLUE
TM (iNtRON Biotechnology, Seongnam,
Korea) according to the manufacturer’s protocol. cDNA was
synthesized from 5 mg of total RNA with reverse transcription and
PCR was performed using 3 ml cDNA with a thermal cycler (Bio-
Rad Laboratories, Hercules, CA, USA). The primer sequences
were as follows: mouse IP-10, forward 59-GATGGCTAGTCC-
TAATTGCCCTTGG-39, reverse 59-CTGAGTATCTTGATA-
ACCCCTTGGG-39; b-actin, forward 59-GTCACCAACTGG-
GACGACA-39, reverse 59-TGGCCATCTCTTGCTCGAA-39.
For RPA, the mCK-5 multi-riboprobe was purchased from
Pharmingen (BD Biosciences) and prepared following the
manufacturer’s guidelines. Total RNA (15 mg) was hybridized
with the riboprobe as described previously [17]. Quantification of
the protected RNA fragments was performed by scanning with a
PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA).
Values for mRNA expression were normalized to GAPDH mRNA
levels for each experimental condition.
Plasmids, transient transfection, and reporter assays
The IP-10-luc luciferase reporter plasmids containing 330 bp of
the murine IP-10 promoter were generated by PCR [55]. For
overexpression of PML protein, the pCMV-Tag2B-PML-IV
expression construct was used [53]. For reporter assays, 0.4 mg
of the IP-10-luc construct was transiently transfected into 0.5610
5
NIH3T3 cells in 12-well plates, with 0.1 mg of pCMV-b-
galactosidase vector to normalize for transfection efficiency as
described previously [17]. The PML IV expression vector (1 mg)
was co-transfected and differences in the amount of DNA adjusted
with empty vector. Cells recovered for 24 h before treatment IFN-
c (10 ng/ml) for 24 h, then luciferase activity was measured. The
luciferase activity of each sample was normalized to b-galactosi-
dase activity to yield relative luciferase activity (RLA).
Nuclear extracts and electrophoretic mobility shift assays
(EMSA)
EMSA was performed with 10 mg of nuclear extracts as
previously described [17]. Nuclear extracts from NIH3T3 cells
treated with IFN-c for 30 min were incubated with either the IP-
10 sequence (59-TCATCTGATTTCTCAAACAGCTCACG-39)
or consensus STAT-1 sequence (SC-2573, Santa Cruz Biotech-
nology) which was end-labeled with [
32P]ATP for 30 min. For
competition experiments, a 100-molar excess of unlabeled
oligonucleotide was added to the nuclear extracts for 30 min
before addition of the labeled probe. Bound and free DNA were
then resolved by electrophoresis through a 6% polyacrylamide gel
and exposed for autoradiography.
Statistical analysis
Statistical analyses were performed using the Student’s t test to
compare between sample groups, and ANOVA was used to
determine differences among multiple groups. Statistical signifi-
cance of the data was set at P,0.05.
Ethics statement
This study protocol was approved by the Institutional Review
Board (IRB) of the Ewha Womans University Mokdong Hospital
(IRB protocol number: ECT11-20-08). Informed consent had
been obtained from each patient prior to surgery and was waived
in this study by IRB due to the retrospective nature.
Acknowledgments
We thank Dr. Pier Paolo Pandolfi for providing the Pml
+/+ and Pml
2/2
MEFs and PML IV protein expression vector.
Author Contributions
Conceived and designed the experiments: DES HJK ENB YHC.
Performed the experiments: DES HJK SYL SHL SJL YHC. Analyzed
the data: DES HJK JLK SJL ENB YHC. Contributed reagents/materials/
analysis tools: JLK ENB. Wrote the paper: DES ENB YHC.
References
1. Kyrlagkitsis I, Karamanolis DG (2004) Genes and gastric cancer. Hepatogas-
troenterology 51: 320–327.
2. Lee HE, Jee CD, Kim MA, Lee HS, Lee YM, et al. (2007) Loss of promyelocytic
leukemia protein in human gastric cancers. Cancer Lett 247: 103–109.
3. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, et al. (2004) Loss of
the tumor suppressor PML in human cancers of multiple histologic origins. J Natl
Cancer Inst 96: 269–279.
4. Borrow J, Goddard AD, Sheer D, Solomon E (1990) Molecular analysis of acute
promyelocytic leukemia breakpoint cluster region on chromosome 17. Science
249: 1577–1580.
5. de The H, Lavau C, Marchio A, Chomienne C, Degos L, et al. (1991) The
PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in
acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:
675–684.
Effect of PML on Lymphocyte Infiltration in Cancer
PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e262646. Goddard AD, Borrow J, Freemont PS, Solomon E (1991) Characterization of a
zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia.
Science 254: 1371–1374.
7. Kakizuka A, Miller WH, Jr., Umesono K, Warrell RP, Jr., Frankel SR, et al.
(1991) Chromosomal translocation t(15;17) in human acute promyelocytic
leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell
66: 663–674.
8. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, et al. (1991)
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha
cDNA and characterization of its retinoid-binding and transactivation
properties. Oncogene 6: 1285–1292.
9. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, et al. (1998) Role of PML in
cell growth and the retinoic acid pathway. Science 279: 1547–1551.
10. LaMorte VJ, Dyck JA, Ochs RL, Evans RM (1998) Localization of nascent RNA
and CREB binding protein with the PML-containing nuclear body. Proc Natl
Acad Sci U S A 95: 4991–4996.
11. Wu WS, Xu ZX, Ran R, Meng F, Chang KS (2002) Promyelocytic leukemia
protein PML inhibits Nur77-mediated transcription through specific functional
interactions. Oncogene 21: 3925–3933.
12. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, et al. (2001) Role of PML
and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell 7:
1233–1243.
13. Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, et al. (2001) The growth
suppressor PML represses transcription by functionally and physically
interacting with histone deacetylases. Mol Cell Biol 21: 2259–2268.
14. Vallian S, Gaken JA, Gingold EB, Kouzarides T, Chang KS, et al. (1998)
Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia
protein. Oncogene 16: 2843–2853.
15. Cairo S, De Falco F, Pizzo M, Salomoni P, Pandolfi PP, et al. (2005) PML
interacts with Myc, and Myc target gene expression is altered in PML-null
fibroblasts. Oncogene 24: 2195–2203.
16. Guo A, Salomoni P, Luo J, Shih A, Zhong S, et al. (2000) The function of PML
in p53-dependent apoptosis. Nat Cell Biol 2: 730–736.
17. Choi YH, Bernardi R, Pandolfi PP, Benveniste EN (2006) The promyelocytic
leukemia protein functions as a negative regulator of IFN-gamma signaling. Proc
Natl Acad Sci U S A 103: 18715–18720.
18. Tamura G (2006) Alterations of tumor suppressor and tumor-related genes in
the development and progression of gastric cancer. World J Gastroenterol 12:
192–198.
19. de Visser KE, Coussens LM (2006) The inflammatory tumor microenvironment
and its impact on cancer development. Contrib Microbiol 13: 118–137.
20. Lorusso G, Ruegg C (2008) The tumor microenvironment and its contribution
to tumor evolution toward metastasis. Histochem Cell Biol 130: 1091–1103.
21. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA (2004) The fibroblast:
sentinel cell and local immune modulator in tumor tissue. Int J Cancer 108:
173–180.
22. Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, et al. (2007) Tumor
promotion by tumor-associated macrophages. Adv Exp Med Biol 604: 67–86.
23. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow?
Lancet 357: 539–545.
24. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized
inflammation in the initiation and promotion of malignant disease. Cancer Cell
7: 211–217.
25. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867.
26. Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: linking
microbial infections to chronic inflammation and cancer. Cell 124: 823–835.
27. Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ, Jr., Yokota SJ,
et al. (2007) Characterization of human lung tumor-associated fibroblasts and
their ability to modulate the activation of tumor-associated T cells. J Immunol
178: 5552–5562.
28. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated
macrophages in tumour progression: implications for new anticancer therapies.
J Pathol 196: 254–265.
29. Maltby S, Khazaie K, McNagny KM (2009) Mast cells in tumor growth:
angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys
Acta 1796: 19–26.
30. Takanami I, Takeuchi K, Naruke M (2000) Mast cell density is associated with
angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 88:
2686–2692.
31. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer
immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:
991–998.
32. Vazquez-Cintron EJ, Monu NR, Frey AB (2010) Tumor-induced disruption of
proximal TCR-mediated signal transduction in tumor-infiltrating CD8+
lymphocytes inactivates antitumor effector phase. J Immunol 185: 7133–7140.
33. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, et al. (2003)
CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are
associated with favorable prognosis in human non-small cell lung cancers.
Cancer Sci 94: 1003–1009.
34. Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, et al. (2010) Increase of
programmed death-1-expressing intratumoral CD8 T cells predicts a poor
prognosis for nasopharyngeal carcinoma. Mod Pathol 23: 1393–1403.
35. O’Hayre M, Salanga CL, Handel TM, Allen SJ (2008) Chemokines and cancer:
migration, intracellular signalling and intercellular communication in the
microenvironment. Biochem J 409: 635–649.
36. Ben-Baruch A (2006) The multifaceted roles of chemokines in malignancy.
Cancer Metastasis Rev 25: 357–371.
37. Lee EY, Lee ZH, Song YW (2009) CXCL10 and autoimmune diseases.
Autoimmun Rev 8: 379–383.
38. Stadler M, Chelbi-Alix MK, Koken MH, Venturini L, Lee C, et al. (1995)
Transcriptional induction of the PML growth suppressor gene by interferons is
mediated through an ISRE and a GAS element. Oncogene 11: 2565–2573.
39. Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ, et al. (2009) IP-10-
mediated T cell homing promotes cerebral inflammation over splenic immunity
to malaria infection. PLoS Pathog 5: e1000369.
40. Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud O (2006) T
lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML):
local release by native human AML blasts and systemic levels of CXCL10 (IP-
10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother 55:
830–840.
41. Neville LF, Mathiak G, Bagasra O (1997) The immunobiology of interferon-
gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-
X-C chemokine superfamily. Cytokine Growth Factor Rev 8: 207–219.
42. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, et al. (2003)
Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic
hepatitis C virus infection correlates with histological severity and lobular
inflammation. J Leukoc Biol 74: 360–369.
43. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, et al. (2001) Proliferative
activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human
renal cell carcinoma: clinicopathologic demonstration of antitumor immunity.
Cancer Res 61: 5132–5136.
44. Zhang P, Chin W, Chow LT, Chan AS, Yim AP, et al. (2000) Lack of expression
for the suppressor PML in human small cell lung carcinoma. Int J Cancer 85:
599–605.
45. Bollrath J, Greten FR (2009) IKK/NF-kappaB and STAT3 pathways: central
signalling hubs in inflammation-mediated tumour promotion and metastasis.
EMBO Rep 10: 1314–1319.
46. Naugler WE, Karin M (2008) The wolf in sheep’s clothing: the role of
interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14:
109–119.
47. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, et al. (2007) Mutations in the
EGFR kinase domain mediate STAT3 activation via IL-6 production in human
lung adenocarcinomas. J Clin Invest 117: 3846–3856.
48. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al.
(1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in
human U266 myeloma cells. Immunity 10: 105–115.
49. Ancrile B, Lim KH, Counter CM (2007) Oncogenic Ras-induced secretion of
IL6 is required for tumorigenesis. Genes Dev 21: 1714–1719.
50. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, et al. (2009)
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-
cycle progression during colitis-associated tumorigenesis. Cancer Cell 15:
91–102.
51. Kawasaki A, Matsumura I, Kataoka Y, Takigawa E, Nakajima K, et al. (2003)
Opposing effects of PML and PML/RAR alpha on STAT3 activity. Blood 101:
3668–3673.
52. Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP, et al. (2003)
Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced
apoptosis by inhibiting the NF-kappaB survival pathway. J Biol Chem 278:
12294–12304.
53. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, et al. (2004)
PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell
Biol 6: 665–672.
54. Fruman DA, Pai SY, Burakoff SJ, Bierer BE (1995) Characterization of a mutant
calcineurin A alpha gene expressed by EL4 lymphoma cells. Mol Cell Biol 15:
3857–3863.
55. Ohmori Y, Hamilton TA (1993) Cooperative interaction between interferon
(IFN) stimulus response element and kappa B sequence motifs controls IFN
gamma- and lipopolysaccharide-stimulated transcription from the murine IP-10
promoter. J Biol Chem 268: 6677–6688.
Effect of PML on Lymphocyte Infiltration in Cancer
PLoS ONE | www.plosone.org 12 October 2011 | Volume 6 | Issue 10 | e26264